WATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today reported financial results and key operational highlights for the second quarter ended June 30, 2014. The Company’s lead antibiotic candidate, eravacycline, is currently in Phase 3 development to treat bacterial infections, including those caused by many of the multidrug-resistant (MDR) Gram-negative bacteria highlighted as urgent public health threats by the Centers for Disease Control and Prevention (CDC).
“During the second quarter we made great progress in our eravacycline development program,” said Guy Macdonald, Tetraphase President and Chief Executive Officer. “We completed enrollment in the lead-in portion of IGNITE 2, our Phase 3 trial in complicated urinary tract infections (cUTI), and recently announced completion ahead-of-schedule of enrollment of IGNITE 1, our Phase 3 trial in complicated intra-abdominal infections (cIAI). We were also delighted that both the intravenous and oral formulations of eravacycline were granted Fast Track designation by the FDA for the treatment of cIAI and cUTI during the quarter.”
Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available. Help employers find you! Check out all the jobs and post your resume.
